News

BIO-CAT Partners with Kerry for Global Distribution of OPTI-BIOME MB40 Probiotic

BIO-CAT, Inc. has formed a global partnership with Kerry, the Taste & Nutrition company and their BIO-CAT Microbials, LLC probiotic products division. Effective June 2021, Kerry will lead the sales, marketing, and distribution of BIO-CAT’s proprietary probiotic strain, OPTI-BIOME MB40®.

OPTI-BIOME MB40® (Bacillus subtilis ATCC122264) is a non-GMO, highly-stable probiotic strain that the company says is an ideal ingredient for a wide array of dietary supplements and other related uses. A 2019 peer-reviewed study demonstrated promising results for the probiotic strain to support gastrointestinal health.

Kerry has extensive success marketing probiotics — the Ireland-based company has placed its GanedenBC30® (Bacillus coagulans GBI-30, 6086) probiotic in well over 1,000 food and beverage products around the world. BIO-CAT CEO Chris Schuler said he envisions similar success with MB40® in the dietary supplement space.

“Given the impressive performance of the MB40® strain and its potential to have a significant impact on the dietary supplement, functional food and beverage, and companion animal industries, we have decided to work with a partner who will help scale MB40® globally,” Schuler said. “Kerry’s expertise, commitment to develop a leading probiotic platform, access to global resources, and plans to further scientifically support MB40® make them an ideal partner.”

As part of the agreement, Kerry will apply its brand development capabilities to refresh the MB40® brand over the course of the coming months. Once fully developed, the new brand name will be supported by Kerry’s global marketing and commercial infrastructure — the company currently boasts a network of nearly 150 locations across 31 countries. According to John Quilter, VP & General Manager of Kerry’s ProActive Health business, “We are delighted to partner with Bio-Cat to further develop and market this unique and highly-stable Bacillus strain, which will complement our growing portfolio of science-backed branded ingredients in our ProActive Health portfolio.”

Recent News

03/24/2026

ReAlta Life Sciences Appoints Howard Berman, Ph.D., as CEO and Kia Motesharei, Ph.D., as President and COO

ReAlta Life Sciences Inc., a clinical-stage biopharmaceutical company focused on safely targeting neutrophils and central components of the complement system to revolutionize the treatment of inflammatory disorders, today announced the appointments of Howard Berman, Ph.D., as Chairman and Chief Executive Officer and Kia Motesharei, Ph.D., as President and Chief Operating Officer. Dr. Berman, who has

03/19/2026

GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C

GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced a new genetic testing program with Zevra Therapeutics, Inc. (Nasdaq: ZVRA), a commercial-stage biopharmaceutical company focused on bringing life-changing therapeutics to people living with rare diseases. The Niemann-Pick Disease type C (NPC) Sponsored Genetic Testing

03/18/2026

Phlow Corp. Appoints Dawn Von Rohr as Chief Operating Officer to Advance Domestic Pharmaceutical Manufacturing

Phlow Corp., a leading American advanced pharmaceutical contract development and manufacturing organization (CDMO), today announced that Dawn Von Rohr has been appointed Chief Operating Officer (COO). Von Rohr will oversee Phlow’s operations, manufacturing execution, and strategic growth initiatives as the company continues expanding its advanced pharmaceutical development and manufacturing infrastructure in the United States to